AMYLYX PHARMACEUTICALS INC (AMLX)
Health Care · Biotechnology · NASDAQ
Amylyx Pharmaceuticals is a clinical-stage biotech developing novel treatments for rare endocrine and neurodegenerative conditions, with a late-stage lead candidate for post-bariatric hypoglycemia.
What AMYLYX PHARMACEUTICALS INC does
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing therapies for endocrine and neurodegenerative diseases with high unmet medical needs. Its lead investigational asset is avexitide, a GLP-1 receptor antagonist in late-stage development for post-bariatric hypoglycemia (PBH). The company's pipeline also includes programs targeting Wolfram syndrome, ALS, and other rare diseases.
Themes: rare diseases, metabolic disorders, GLP-1 receptor antagonist, neurodegenerative diseases, post-bariatric hypoglycemia (PBH)
Fundamentals
- Price$38.66 as of 2026-08-21 close
- Market cap$4.3B as of 2026-08-21
- 1-year return+358.6% 2025-08-21 close $8.43 → 2026-08-21 close $38.66
- P/En/a negative earnings
- Net margin-94.6% as of 2026-08-24
- Gross margin+82.8% as of 2026-08-24
- ROE-52.9% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta-0.10 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How AMLX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AMLX is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
53.4 #581 of 1,704 scored · #107 of 240 in Health Care
Trend 98th: a strong uptrend, with buyers in control; volume and participation 78th: trading volume is about normal versus its 30-day average; weakest is setup 34th: day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months). Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How AMYLYX PHARMACEUTICALS INC looks technically
AMYLYX PHARMACEUTICALS INC (AMLX) is trading 145.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 435 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 53, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 82, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day high about 2 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 145.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +145.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $20.27 | $20.27 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.74 | $15.74 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 19.15. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 435 trading days ago — a "golden cross", a bullish long-term signal | 435 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 53, with buyers in control | 52.9 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 82, in overbought territory (above 70) | 82.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($20.32 to $41.14) — its "stochastic" reading is 88 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 88.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $41.14 | $41.14 |
|---|---|---|
| From the 52-week high | it is 6.0% below its 52-week high (its highest price of the past year) | -6.0% |
| Above the 52-week low | it is 406.7% above its 52-week low (its lowest price of the past year) | +406.7% |
| Below the 52-week high | it is 6.0% below its highest point of the past year | 6.0% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $41.92 (set on 2023-01-30) | $41.92 |
| Given back of the 52-week move | over the past year its closes ranged ($7.82 to $39.66), and it has given back only a small part of its rise from last year’s low — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $18.96 to $19.98. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.1% |
| From the all-time high | it is 7.8% below its all-time high | -7.8% |
| Nearest price level | it is trading 60.4% above a support level at $15.30 — a price it turned at four times since 2025-09-30, most recently on 2026-04-29. Since 2024-08-21 it has 10 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -60.4% |
| All-time low | its lowest closing price on record is $1.57 (set on 2024-06-17) | $1.57 |
| Above the all-time low | it is 2354.6% above its all-time low | +2,355% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.42 between its high and its low — about 6.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.42 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.44 and $38.35 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.44 – $24.90 – $38.35 |
| Typical daily range (% of price) | its price moves about 6.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.3% |
| Stretch from the 200-day average | it is trading 9.5 daily ranges above its 200-day average price (145.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 9.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.54× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.2% since the prior reading | +0.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 2.9% above the previous close 2 sessions ago and has not traded back through the level it left behind at 35.11 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.9% |
| Gap filled | a 2.9% gap down opened on 2026-08-20 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 106.6 percentage points (the stock gained 109.0% while the market gained 2.3%) | +106.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 174.4 percentage points (the stock gained 177.5% while the market gained 3.1%) | +174.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 164.9 percentage points (the stock gained 175.9% while the market gained 11.1%) | +164.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 338.1 percentage points (the stock gained 358.6% while the market gained 20.5%) | +338.1% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 130% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.6% of the share price. | +130.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 94% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $19.96 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +93.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 15% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $33.75 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +14.6% |
Price levels it has turned at before
AMLX last closed at $38.66 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $15.30 | Support | 60.4% below the last close | turned there four times · 2025-09-30 to 2026-04-29 |
| $13.57 | Support | 64.9% below the last close | turned there twice · 2026-02-19 to 2026-03-09 |
| $12.65 | Support | 67.3% below the last close | turned there twice · 2026-03-30 to 2026-06-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $19.15.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $20.56 and $22.69 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.18 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$27.50 range $20.00 – $40.00; median $27.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AMLX
- Consensus EPS estimate-$0.365 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Company is currently unprofitable and dependent on successful clinical trial results and regulatory approval of its investigational therapies.","High execution risk associated with clinical trial outcomes and the potential for regulatory rejection or delay.","Limited operational history and high cash burn rate characteristic of clinical-stage biotechnology firms."]
What changed in the latest 10-Q
AI-assisted comparison of AMLX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to '2025 Annual Report' instead of '2024 Annual Report' in forward-looking statements disclaimer (filed 2026-05-07)
- Added 'AMX0318 in PBH and other rare diseases' to pipeline description (filed 2026-05-07)
- Added detailed PBH epidemiology: 'approximately 160,000 people in the U.S.' described as '8% of people in the U.S. who have undergone the two most common types of bariatric surgery' (filed 2026-05-07)
- Added expanded PBH description: 'chronic metabolic condition' and detailed discussion of neuroglycopenia, disability impacts, and quality of life effects (filed 2026-05-07)
- Added specific description of avexitide mechanism as 'competitively bind to the GLP-1 receptor on pancreatic islet beta cells' (filed 2026-05-07)
- Added LUCIDITY trial specifics: '78-participant' enrollment completed 'in March 2026' at '21 sites' (filed 2026-05-07)
- Added up-to-six-week screening period details to LUCIDITY trial structure (filed 2026-05-07)
- Added information about specific types of surgeries in Phase 2b trial: 'esophagectomy, Nissen fundoplication, and gastrectomy' beyond RYGB and sleeve gastrectomy (filed 2026-05-07)
- Added statement: 'In July 2025, we presented new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials' as standalone sentence (filed 2026-05-07)
- Removed:
- Removed description of Gubra A/S collaboration for developing long-acting GLP-1 receptor antagonist and timeline for development candidate nomination (filed 2025-11-06)
- Removed reference to 'three investigational therapies' and changed to 'four investigational therapies' (filed 2026-05-07)
- Removed description of avexitide as 'first-in-class inhibitor of glucagon-like peptide-1' and updated to 'first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist' (filed 2026-05-07)
- Removed 'Rare Pediatric Disease Designation in congenital HI' phrasing and updated (filed 2026-05-07)
- Removed broader PBH description as 'a condition' and changed to 'a chronic metabolic condition' (filed 2026-05-07)
- Removed phrasing 'PBH is thought to be caused by an excessive GLP-1 response' and expanded it (filed 2026-05-07)
- Removed 'approximately 75 participants' will be randomized and updated to 'Participants were randomized' with specific count of 78 (filed 2026-05-07)
- Removed 'approximately 20 sites' and updated to '21 sites' (filed 2026-05-07)
- Removed 'We expect to complete recruitment in the first quarter of 2026' and replaced with 'Enrollment for LUCIDITY was completed in March 2026' (filed 2026-05-07)
- Removed detailed explanation of exploratory analyses as bullet point and integrated into main narrative (filed 2026-05-07)
- Removed abbreviation 'PK' and replaced with 'pharmacokinetic' in newer text (filed 2026-05-07)
- Reworded:
- Changed 'develop novel therapies' to 'develop and advance novel therapies' (filed 2026-05-07)
- Changed 'where we believe they can make the greatest impact' to 'for which we believe these therapies can make the greatest impact' (filed 2026-05-07)
- Changed 'mechanistic rationale' to 'mechanistic rationales' (filed 2026-05-07)
- Changed 'congenital hyperinsulinism, or HI' to 'congenital hyperinsulinism, or congenital HI' (filed 2026-05-07)
- Changed 'Rare Pediatric Disease Designation in congenital HI' to 'Rare Pediatric Disease Designation for congenital HI' (filed 2026-05-07)
- Changed 'Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI)' to 'Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia' (filed 2026-05-07)
- Changed 'about 160,000 people' to 'approximately 160,000 people' (filed 2026-05-07)
- Changed 'PBH is thought to be caused by' to 'PBH is thought to be driven by' (filed 2026-05-07)
- Changed 'excessive GLP-1 response' to 'exaggerated GLP-1 response, primarily in response to food intake' (filed 2026-05-07)
- Changed 'hypoglycemia and impaired quality of life' to more detailed description with clinical manifestations (filed 2026-05-07)
- Changed reference to 'randomized, blinded, placebo-controlled' to 'randomized, double-blind, placebo-controlled' (filed 2026-05-07)
- Changed 'randomized 3:2 to receive either' phrasing from prospective to past tense 'Participants were randomized' (filed 2026-05-07)
- Changed 'Approximately 75 participants' to specific '78-participant' count (filed 2026-05-07)
- Changed 'approximately 20 sites' to '21 sites' (filed 2026-05-07)
- Changed 'following RYGB surgery and other upper-gastrointestinal surgeries' to list specific surgeries (filed 2026-05-07)
- Changed 'vs.' to 'versus' in presentation of statistical results (filed 2026-05-07)
- Changed 'PK and pharmacodynamic, or PD' to 'pharmacokinetic and pharmacodynamic' (filed 2026-05-07)
- Changed 'five clinical trials' to 'five previous clinical trials' (filed 2026-05-07)
- Notes:
- Older filing text appears truncated at end ('In congenital HI, we are actively engaging in discussions with the broader con'), limiting full comparison of congenital HI section
- Page numbers differ between filings (16 vs 17), suggesting layout/formatting changes independent of content
Risk Factors
- Added:
- In the summary list, added "AMX0318" as a product candidate mentioned in the collaborations risk factor (filed 2026-05-07)
- In the summary list, reordered bullet points under "Risks Related to Our Business Operations and Employee Matters" - moved "We are continuously evaluating and pursuing strategic transactions..." bullet earlier in the list (filed 2026-05-07)
- Removed:
- Removed the opening phrase "We have ceased marketing and selling our previous commercial product in the U.S. and Canada and will therefore not continue to generate revenue from this product for the treatment of ALS." from the first bullet point in the summary list (filed 2026-05-07)
- Removed reference to "AMX0318" in the collaborations risk factor (older filing included only "AMX0114") - newer filing added AMX0318 (filed 2026-05-07)
- In the detailed section, removed "and toward the commercialization of AMX0035" text that appeared in the older version (filed 2025-11-06)
- Removed the phrase "and capital markets disruption" from the economic uncertainty risk factor (filed 2026-05-07)
- Removed specific references to "the Israel-Hamas conflict" from the geopolitical instability risk factor (filed 2026-05-07)
- Removed reference to "a new U.S. presidential administration and accompanying regulatory activities and economic policies" and replaced with more general language (filed 2026-05-07)
- Reworded:
- Changed "Risks Related to Commercialization of Avexitide, AMX0035 or Future Product Candidates" to lowercase 'avexitide' in the header (filed 2026-05-07)
- Updated geopolitical reference from "the ongoing war between Russia and Ukraine, the Israel-Hamas conflict and conflict in the Middle East" to "the ongoing conflicts between Russia and Ukraine, and the U.S. and Iran, and in the Middle East" (filed 2026-05-07)
- Changed "a new U.S. presidential administration and accompanying regulatory activities and economic policies" to "the evolving regulatory activities and policy changes under the current U.S. government" (filed 2026-05-07)
- Collaboration risk factor changed from "AMX0114 or any other" to "AMX0114, AMX0318 or any other" and from "with respect to avexitide, AMX0035, AMX0114 and" to "with respect to avexitide, AMX0035, AMX0114, AMX0318 and" (filed 2026-05-07)
- Notes:
- The newer filing text appears truncated in the provided source, ending mid-sentence in the detailed risk discussion, so comparison of the full detailed sections is incomplete
- Page numbers differ between filings (26-28 in newer vs. 30-32 in older), consistent with different document lengths
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($538868) — 1 selling insider
- Last 180 days1 buy ($51338) · 3 sells ($962628) — 1 buying, 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-10. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AMLX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding AMLX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 28,292,170
- Reported value $393,261,160
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AMLX had 13,401,722 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AMLX had 12.0% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.84 days to cover at the same settlement.
- Reported short interest (shares) 13,401,722
- Short interest (% of shares outstanding) 12.0%
- Prior settlement (shares) 12,265,993
- Reported change 9.26%
- Days to cover (reported) 6.84
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
AMYLYX PHARMACEUTICALS INC is found in…
Frequently asked questions
What does AMYLYX PHARMACEUTICALS INC (AMLX) do?
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing therapies for endocrine and neurodegenerative diseases with high unmet medical needs. Its lead investigational asset is avexitide, a GLP-1 receptor antagonist in late-stage development for post-bariatric hypoglycemia (PBH). The company's pipeline also includes programs targeting Wolfram syndrome, ALS, and other rare diseases.
What sector is AMYLYX PHARMACEUTICALS INC (AMLX) in?
AMYLYX PHARMACEUTICALS INC (AMLX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is AMYLYX PHARMACEUTICALS INC (AMLX) overbought or oversold right now?
AMYLYX PHARMACEUTICALS INC (AMLX) is currently in overbought territory (its 14-day RSI is 82, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AMLX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.